Evidence map›Paper›PMID 38668819›Full record

SynthesisGastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association2024

Revisiting the use of the EORTC QLQ-STO22 to assess health-related quality of life of patients with gastric cancer: incorporating updated treatment options and cross-cultural perspectives.

S C Sodergren, A Hurley-Wallace, V Vassiliou, B Alkhaffaf, B Batsaikhan, A S Darlington, T Fleitas-Kanonnikof, M G Guren, M Honda, Y W Kim and 12 more

Abstract readSystematic Review
PubMed Full text at PMC Publisher
In one paragraph

Synthesis in Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

22 authors.

S C SodergrenSchool of Health Sciences, University of Southampton, Southampton, SO17 1BJ, UK. S.C.Sodergren@soton.ac.uk.ORCID 0000-0001-8755-146X
A Hurley-WallaceSchool of Health Sciences, University of Southampton, Southampton, SO17 1BJ, UK.
V VassiliouMedical Oncology Department, Bank of Cyprus Oncology Centre, Nicosia, Cyprus.
B AlkhaffafDepartment of Oesophago-Gastric & Bariatric Surgery, Northern Care Alliance NHS Foundation Trust, Salford, UK.
B BatsaikhanDepartment of Internal Medicine, Institute of Medical Sciences, Mongolian National University of Medical Sciences, Ulaanbaatar, Mongolia.
A S DarlingtonSchool of Health Sciences, University of Southampton, Southampton, SO17 1BJ, UK.
T Fleitas-KanonnikofMedical Oncology Department, Hospital Clinico Universitario de Valencia, Valencia, Spain.
M G GurenInstitute of Clinical Medicine, University of Oslo, Oslo, Norway.
M HondaGeneral South Tohoku Hospital, Koriyama, Japan.
Y W KimCenter for Gastric Cancer, National Cancer Center, Goyang-si, Korea.
S KimCenter for Gastric Cancer, National Cancer Center, Goyang-si, Korea.
M N KrishnamurthyDepartment of Clinical Pharmacology, Tata Memorial Centre, Tirupati, India.
S Y LohFaculty of Medicine, University of Malaya, Kuala Lumpur, Malaysia.
N S TurhalAnadolu Medical Center, Çayırova, Turkey.
J ZhouDepartment of General Surgery, The First Affiliated Hospital of Soochow University, Suzhou, China.
K DennisDivision of Radiation Oncology, The Ottawa Hospital Cancer Centre, Ottawa, Canada.
R KrishnatryDepartment of Radiation Oncology, Tata Memorial Centre, Tirupati, India.
M TerashimaDivision of Gastric Surgery, Shizuoka Cancer Center, Shizuoka, Japan.
G TsironisMedical Oncology Department, Bank of Cyprus Oncology Centre, Nicosia, Cyprus.
T YoshikawaDepartment of Gastric Surgery, National Cancer Center Hospital, Tokyo, Japan.
M TeradaDepartment of International Clinical Development/International Trials Management Section, National Cancer Center Hospital, Tokyo, Japan.
EORTC Quality of Life Group

Funding

European Organisation for Research and Treatment of Cancer 003-2019
6 · The paper itself

Abstract

backgroundThe EORTC QLQ-STO22 (QLQ-STO22) is a firmly established and validated measure of health-related quality of life (HRQoL) for people with gastric cancer (GC), developed over two decades ago. Since then there have been dramatic changes in treatment options for GC. Also, East Asian patients were not involved in the development of QLQ-STO22, where GC is most prevalent and the QLQ-STO22 is widely used. A review with appropriate updating of the measure was planned. This study aims to capture HRQoL issues associated with new treatments and the perspectives of patients and health care professionals (HCPs) from different cultural backgrounds, including East Asia.

methodsA systematic literature review and open-ended interviews were preformed to identify potential new HRQoL issues relating to GC. This was followed by structured interviews where HCPs and patients reviewed the QLQ-STO22 alongside new issues regarding relevance, importance, and acceptability.

resultsThe review of 267 publications and interviews with 104 patients and 18 HCPs (48 and 9 from East Asia, respectively) generated a list of 58 new issues. Three of these relating to eating small amounts, flatulence, and neuropathy were recommended for inclusion in an updated version of the QLQ-STO22 and covered by five additional questions.

conclusionsThis study supports the content validity of the QLQ-STO22, suggesting its continued relevance to patients with GC, including those from East Asia. The updated version with additional questions and linguistic changes will enhance its specificity, but further testing is required.

Indexed as

Quality of LifeStomach NeoplasmsAdultAgedCross-Cultural ComparisonFemaleHumansMaleMiddle AgedSurveys and QuestionnairesCross-cultural comparisonEORTC QLQ-STO22Gastric cancerHealth-related quality of life

Identifiers

PMID38668819
PMCPMC11193686

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.